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1. Introduction 
About 68,130 new melanomas will be diagnosed in the United States during 2010 (38,870 
men: 29,260 women) and of those 8,700 people will die of the disease (5,670 men; 3,030 
women). The death rate has been dropping since the 1990s for those younger than 50, but 
has remained stable or is rising for older individuals. However, the incidence of melanoma 
has been increasing for at least 30 years, and this trend has become more pronounced in 
young white females and in older white men1. 
Malignant Melanoma is the seventh most common type of cancer, but it is the first cause of 
death from cutaneous skin cancers2. It has been estimated that the lifetime risk of 
developing malignant melanoma is 2% (1 in 50) for Caucasians, 0.1% (1 in 1,000) for those of 
black descent, and 0.5% (1 in 200) for Hispanics3 .  
When melanoma is detected in advanced stages, it carries a dismal prognosis, with a 
mean survival of about 8 months and a 5-year survival as low as 5% 4-6. The disease 
spreads both by the lymphogenous and the haematogenous routes and can metastasize to 
virtually any organ in the body. When secondary tumours emerge, these usually follow a 
sequential pattern to regional lymph node basins, followed by distant sites including skin, 
subcutaneous tissue, lung, liver, brain, bone and other viscera5-6. Local recurrence, in-
transit metastases and satellitosis (cutaneous metastases within 2 cm of original lesion) 
represent the same dissemination process4 in the dermal lymphatics. When the patients 
present with cutaneous metastases, they are considered to have stage IIIB disease7. 
Cutaneous metastases occur in 2-20% of patients, depending on tumor thickness 6, 8-9 and 
can occur either during the early or late phase of the disease 10. In many instances they can 
represent the first site of recurrence after surgical excision of the primary tumor 11 . The 
majority (70-80%) of recurrences are diagnosed within the first 3 years of initial diagnosis, 
and the median time to the presence of in-transit disease could range between 3 to 16 
months4. The recurrences present as local or in-transit disease in 20-28%, regional disease 
in 26-60% and as distant metastases in 15-50% of patients. Even though local recurrence is 
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not yet considered stage IV disease, the prognosis is poor with 5 year survival rates of less 
than 50% 9,12. The risk of developing metastases may be predicted at excision of the 
primary lesion and determinants include, increasing thickness of the tumour, the 
anatomical location, histological subtype and gender 13. In general tumours of the trunk, 
non cutaneous and subungual regions behave more aggressively than those of the 
extremity 14-16 .  
2. Treatment limitations for recurrent or in-transit melanoma  
Treating extensive cutaneous/subcutaneous nodules or in-transit disease is a clinical 
challenge because of common unresectability and relative insensitivity to conventional 
systemic therapies6. These recurrences provide a significant psychological burden for 
patients whose quality of life is negatively affected by the symptoms caused by the tumor, 
such as pain, bleeding, ulceration, and malodorous discharge 4, 17-18. Many patients suffering 
from in-transit disease also manifest with systemic disease, within 6-13 months of the onset 
of the local lesions. Their life expectancy is foreshortened and is determined by factors such 
as the burden of the loco-regional disease, the interval from initial treatment and their 
immune status 4.  
The aim of the treatment should be the elimination of both local and systemic disease with 
the benefit of improved life expectancy and quality of life, while minimizing toxicities or 
deformities. It is important to note that metastatic cells have disseminated prior to surgical 
intervention, outlining the critical need for the development of adjuvant therapeutic 
strategies19. Thus the treatment of unresectable and in-transit disease is both systemic and 
loco/regional. The options include surgery, which is the most effective method for limited 
recurrent or in-transit disease, systemic chemotherapy12,21, radiation therapy22, 
cryosurgery23; carbon dioxide laser ablation,12,24-26, intralesional therapies12,21 with the Bacille 
Calmette-Guerin vaccine27, TNFerade a non replicant adenovirus complex, expressing the 
Tumor Necrosis Factor alpha (TNF-α) gene (hTNF-α cDNA)12,28, and Interleukin-229, Cell 
Vaccine and Immunotherapy 30-33, Interferon alpha34-36, Regional therapies such as 
hyperthermic isolated limb perfusion (HILP) and Isolated limb infusion (ILP)37, Novel 
Molecular Therapies with c-Kit inhibitors (Imatinib), C-RAF-inhibitors (Sorafenib) 38, and 
blocking B-RAF regulation of mitogen-activated protein kinase pathway (MAPK) 38. In more 
recent years electroporation with anticancer drugs which is termed electrochemotherapy 
(ECT) has been successfully applied for local tumour control 17, 19, 39. In general malignant 
melanoma is refractory to systemic treatments and survival after treatment of regional 
cutaneous metastases has been reported to be between 20-28% at 10 years6,9,40. However all 
current treatment modalities have individual limitations and variable response rates 4, 12, 19, 
41-42. 
3. Electrochemotherapy (ECT) 
Definition and physiological effect: 
The cell membrane represents a physical barrier to the intracellular transfer of hydrophilic 
drugs, macromolecules, nucleotides and peptides. The movement of polar and hydrophilic 
molecules across the membrane is restricted by the phospholipid bilayer18 Studies suggest 
that exposure to sufficiently strong and long electrical fields, could rearrange the lipid 
bilayer, by reorienting the hydrophillic heads in pore-like fashion, while the hydrophobic 
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tails are embedded within the plasma membrane. This porosity is transient and reversible if 
short duration high amplitude square wave electrical pulses are optimized.18 
Electroporation (EP) of tumour nodules allow the permeation, into the cancer cells, of poorly 
permeable antineoplastic drugs, such as bleomycin or cisplatin which are given either 
systemically or intratumorally (IT)18, 39, 43-46  
The temporary permeability of the cell membrane caused by the electric pulses facilitates a 
potent localized effect and magnifies the drugs cytotoxicity by orders of magnitude 18, 39, 46-50.  
Types of Drugs 
After several studies of different cytotoxic drugs, two have been identified as the best 
candidates for ECT: Bleomycin and Cisplatin 17, 45. Of importance in these studies EP or the 
drugs on their own do not influence the growth of tumours, yet their combination have 
potent tumoricidal effects18, 51-53 ( See Figure 1). An advantage of ECT is that it requires much 
lower doses of the cytotoxic drug for optimal effects than those usually used for systemic 
treatments. In addition there is little in the way of collateral damage or complications, since 
the the cell killing is confined to the tissues affected by the electric field. Bleomycin 
intercalates into the cellular chromatin causing single and double stranded breaks in DNA 
resulting in a mitotic cell death by pseudoapoptosis. ( Figure 1 B,C & D). On the other hand, 
Cisplatin creates an apoptosis effect on the cell 18, 46. This cytolytic activity is potentiated 
more than 1,000 fold for Bleomycin and 100 fold for Cisplatin by the addition of EP 12, 19, 48-49.  
The Vascular Lock  
The electric pulses produce a transient state of hypoperfusion by local reflex 
vasoconstriction at the arteriolar level (lasting 1-2 minutes) and a phase of interstitial edema 
(that resolves with membrane resealing). However the effect may last longer (12 hours to 5 
days) in rapidly dividing tumor cells and is more prominent in tumours with a less mature 
endothelial lining and higher interstitial pressure. This phenomenon mediated by the 
sympathetic nervous system is termed the “vascular lock” and it has implications for timing 
of drug administration18-19. After application of the electric current, there is a retention of 
drugs already in the tumour but there is also an impairment of entry of drugs from the 
circulation. Thus when the cytotoxic drugs are administered systemically sufficient time 
should be allowed to achieve optimal intratumoral drug concentration prior to application 
of EP. ECT produces other vascular influences, which are believed to be secondary to a 
reduction in local angiogenic factor production, such as endothelial cell destruction and 
neovascular reorganization 46, 54-55. The combined vascular influences have been successfully 
exploited in the treatment of bleeding melanomas 56-57– which may be a difficult to manage 
problem, sometimes refractory and fatal, in patients with unresectable disease. 
4. Technique of electrochemotherapy 
1. The Equipment 
The electric pulses may be applied to the tumors either by plate electrodes on the skin 
surface or by needle electrodes inserted into the lesion (figure2). The electric field 
distribution is determined by the geometry of the electrodes. Regardless of the type of 
electrode the electric field is highest around and between the electrodes 17-18. The current 
pulse generators in use are the Cliniporator (IGEA, Carpi, Italy ) (FIG 2) and the 
MedpulserTM (Inovio Biomedical Corporation, CA, USA). It appears that plate electrodes are 
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Fig. 1. A. Growth curves of experimental cancers in mice, which demonstrate that 
electropermeabilisation or intratumoural bleomycin alone, have no influence on tumour 
growth but when used together completely ablate the tumour.  B) Positive Tunel stain 48 hrs 
post ECT indicating tumor cell death by apoptosis. C &D Tumour before showing normal 
cellularity and  D 48 hrs post ECT showing regions of denucleation  
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more suitable for use in superficial skin lesions, while needle electrodes are used for deeper 
seated lesions, such as exophytic and thick lesions (maximum depth 3 cm)52. A disadvantage 
of plate electrodes over the needle type is the potential skin damage that may be generated 
by the higher impedance/resistance of the skin, especially when treating larger affected 
areas19, 58. Care must be taken to avoid inserting the needle electrodes into the healthy tissue 
surrounding the tumors, which may also result in local subcutaneous burns 39. There are 
three types of electrodes in common usage (FIG 2 ). Type I electrodes consist of two parallel 
stainless-steel plate electrodes, used for superficial lesions and do not penetrate the skin. 
Type II electrodes are used for smaller lesions and consist of two rows of eight needles with 
4 mm distance between them, while Type III electrodes are recommended for larger lesions 
(>1cm), with the needles in a hexagonal configuration. The needles are inserted encircling 
the tumor and down to the subcutaneous tissue, slightly deeper than tumor depth 17, 19, 52, 59 . 
It is recommended to elevate or tent the skin at the time of delivering the electric current , if 
the electrodes are to be inserted in a superficial or shallow subcutaneous areas such as near 
the knees, tibial tuborosities, the scalp, or close to any other osseous structures52  
 
 
 
 
 
 
Fig. 2. (A) The ECT pulse generator. B) Note an entrainment of 8 square wave pulses.   
C) Electrodes type1 (plates) and (D) type 3 (Needle array). 
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2. Anesthesia 
The procedure can be performed in the outpatient or ambulatory setting, under local 
anesthesia in association with conscious sedation. General anesthesia may be preferred for 
larger tumors, or tumors located in prior irradiated or fibrotic tissues where infiltration of 
local anesthetic may be painful and less likely to diffuse and thus achieve adequate pain 
control and for those located too close to vascular or bony structures. The dose of local 
anesthetic should be recorded and should not exceed the maximum allowed per body 
weight for Lidocaine without epinephrin (3 mg/kg ) 52, 59-60. In addition, a mixture of 02/air 
with Fi02 of 40 % is administered to the patients during conscious sedation. 
3. The Electric Current 
Permeabilization occurs in the cell when the internal transmembrane potential has 
surpassed the critical value between 200-300mV. The extent of the electroporative effect 
depends on the number and duration of the electric pulses18,55. Two pulse parameters have 
been evaluated - exponentially decaying pulses and square wave pulses. Of the two, square 
wave pulses are preferred as they permit independent control of the length and amplitude. 
The pulse parameters selected for treatment depend on the type of electrode 18, 52.  
Pulse parameters 
Ideally for Type I (plate) electrodes, pulse parameters of 8 square waves with amplitude of 
1300 V/cm, duration of 100 µs, and frequency of 1Hz are used. The current should be 
delivered in two perpendicular directions.  
For type II (needle) electrodes the voltage amplitude may be reduced to 1000V/cm. The 
pulses are administered simultaneously between the needle pairs.  
For Type III, the needles are positioned hexagonally and 96 pulses are given together (12 
pairs x 8 pulses) at a frequency of 5 kHz 61.  
Due to the already described vascular lock phenomenon, it is recommended that the electric 
current is applied between 8 to 28 minutes after IV administration of the drug62, or 
immediately (within 2-10 minutes) after intratumoral administration 19, 59, 63-64. 
4. Drug Dosage Recommendations 
Initial studies compared the routes of administration of Bleomycin suggested advantages for 
the intralesional over intravenous administration (77% vs. 45 % complete responses) 45 but 
later the prospective multi-institutional ESOPE (European Standard Operating Procedures 
of Electrochemotherapy) study in 2006, concluded that IV or IT Bleomycin were comparable 
when given to tumors of volumes less than 0.5 cm3 52. For Cisplatin, the studies have shown 
that IT is more effective than the IV route, with CR rates of 82% vs. 48% respectively19, 45. In 
the ESOPE study local tumor control was achieved in up to 88% of tumors treated with IV 
Bleomycin, 73% with IT Bleomycin and 75% with IT Cisplatin52. 
If a lack of uniformity of drug distribution within the tumor is anticipated either by the 
presence of large and extensive disease, harder fibrotic tumor nodules, lymphedema or limb 
fibrosis, the IV route would be more suitable 52. The Intratumoral route is more feasible for 
those less perfused nodules located in previously pretreated areas19. 
When Bleomycin is given IV the dose is 15,000 IU/m2 of body surface area in a bolus lasting 
30-45 seconds. But when the IT route is chosen, both drugs are given in a dose calculation 
based on tumor burden. The IT dose of Bleomycin based on tumor size is calculated as 
follows: for tumor nodules less than 0.5 cm3 a dose of 1000 IU/cm3, tumor nodules between 
0.5 and 1 cm3 a dose of 500 IU/cm3 and for tumors larger than 1 cm3 a dose of 250IU/cm3 is 
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administered. The cumulative dose should not exceed 400,000 IU/m2 due to the cumulative 
risk of lung fibrosis46,52. If the cumulative dose surpasses 60,000 IU /m2, objective 
respiratory function tests should be made at intervals and the drug discontinued if the 
respiratory diffusion capacity is abnormal60. The IT dose of Cisplatin is given as follow: for 
nodules less than 0.5 cm3 a dose of 2mg/cm3, for nodules between 0.5-1 cm3, a dose of 
1mg/cm3 and for nodules larger than 1 cm3 a dose of 0.5mg/cm3 is given. (Table 1) 
 
Tumor Volume 
(V=ab2π/6) 
Bleomycin dose 
(1000 IU/mL concentration) 
Cisplastin dose 
(2mg/mL concentration) 
<0.5 cm3 
1 mL/cm3 tumor 
0.5 mL/ cm3 tumor 
0.25 mL/ cm3 tumor 
>0.5 < 1 cm3 
>1 cm3 
Table 1. Tumor volume and IT drug dose concentration 
The rationale for reducing the intralesional dose per cm3 when treating areas with larger 
tumor burdens is to reduce the risk of systemic toxicities of the absorbed drug without 
compromising local efficacy19. 
 Prophylactic antibiotics against skin flora should be given intravenously prior to the start of 
the procedure, especially when lesions are ulcerated or necrotic. 
The required time for the procedure is short, with a median treatment duration of 25 
minutes32. Repeated treatments are usually well tolerated by the patients 11, 65-66 and these 
can usually be performed at 1-6 weekly intervals, without evident resistance 45. 
5. Patient monitoring 
Prior to each treatment session patients should have an electrocardiogram (ECG), blood 
work for evaluation of renal function, coagulation and electrolyte values. All lesions should 
be photographed and the tumor burden documented. Cellular debris may be released from 
the tumour during electroporation and these may interfere with the clearance of cytotoxic 
drugs by the kidney. Thus, when using IV Bleomycin, the serum creatinine should be 
maintained at less than 150mol/L to ensure proper renal clearance. Physiological 
monitoring includes visual display of O2 saturation, pulse rate, blood pressure, continuous 
ECG tracing and respiratory parameters. Acetominophen or an anti-histaminic medication 
may be given to prevent the mild febrile reaction that may occur in the early post procedural 
period when Bleomycin is administered 46, 59. 
Technical pearls 
1. Test the device and the electrodes prior to beginning the procedure 
2. Prep and drape following sterile technique principles 
3. Keep in mind correct timing of drug administration and application of the electric 
current 
4. Protect osseous surfaces by tenting the skin 
5. Communicate with awake patients and assisting staff, prior to delivery of electric 
current 
6. Check electroporator traces and waves to confirm proper current delivery 
7. Do not overlap treating fields with normal tissue 
8. Dress wounds according to presenting symptoms 
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5. ECT development and clinical applications in melanoma 
Neumann in 198267 published the first paper regarding EP as a method to transfer genes into 
mammalian and bacterial cells. There were other in vitro 65, 68 and in vivo studies in early and 
late 1980’s using EP in combination with drugs69, but the first clinical trials demonstrating 
its effectiveness over Bleomycin alone for the treatment of a diversity of cutaneous tumors 
of the head and neck region, were published in early 90’s by Mir et al47 and Belehradek et 
al.70 from the Institute Gustave Roussy, in Villejuif France. These first 8 patients were treated 
for squamous cell carcinoma tumors and a complete response (CR) was observed in 57% of 
the lesions. These early publications encouraged other investigators to expand the principles 
of this technique to other tumor types including basal cell carcinomas, Kaposi sarcoma, and 
melanoma metastases 6, 62, 71-74. By the mid 90’s, Rudolf et al.71 and Heller et al. 73 published 
the results of an initial small group (5) of melanoma patients that underwent treatment with 
ECT and IV Bleomycin. They reported overall response rates (OR) in 92% and 50% of 24 and 
10 metastatic nodules respectively19. That same year, Glass et al. 75 from the University of 
South Florida in Tampa, USA, reported on the first study using ECT with IT Bleomycin in 
melanoma metastases obtaining OR rates of 92% (78% CR and 14 % PR) in 20 metastatic 
lesion – results similar to those obtained by the IV route in the previous studies. Later in 
1998, the same group of investigators published the results of a bigger cohort of patients 
with a variety of cutaneous and subcutaneous malignant nodules. Twelve of 34 patients had 
84 metastatic melanoma nodules with documented OR rates up to 99% (89% complete 
response (CR) and 10 % partial response (PR))76. That same year, the combined data 
produced by five institutions in USA, France and Slovenia was published by Mir et al.39 In 
this study, twenty patients with metastatic melanoma lesions showed responses in 131 
(92%) of 142 lesions, with CR of 53% and PR of 39%. A major finding of this study was that 
the results were comparable among the institutions even though their treatment protocols 
and the route used for administering the Bleomycin were not standardized. Additional 
small studies 56, 77-79 using ECT with IT Bleomycin for melanoma lesions continued to show 
good responses, with OR rates of 71 to 100% (CR 23%-100% and PR 0%-62%). Rols et al.80 in 
2000 continued to demonstrate OR’s of 93% using ECT and IV Bleomycin in the treatment of 
54 metastatic melanoma nodules.  
Sersa et al.81-82 introduced Cisplatin as a therapeutic option in 1998. In their studies they 
reported CR rates of 100% for 2 patients with 13 lesions treated with IT Cisplatin, but low 
CR rates of 11 % in 9 patients with 27 lesions treated using the IV route. Additional studies 
were published using this drug by the IT route only 61, 82-83 with OR rates ranging from 81% 
to 100% (CR 0%-70 % and PR 6%-100%). 
The main issue with most of the studies of the 1990’s and early 2000’s was the utilization of a 
variety of treatment protocols with different pulse parameters and pulse generators in 
combination with different electrode types and drug administration routes 6, 39, 44, 47, 52, 56, 58, 63, 
70, 72-73, 75-78, 81-88. But in 2006 the results of a pivotal prospective non-randomized multicenter 
ESOPE study 52 were published, thus providing recommendations for a standardized 
protocol for the procedure. The study included 102 patients, 61 evaluated for response and 
41 for toxicity respectively. The protocol allowed for administration of Bleomycin either IV 
or IT, or with Cisplatin IT, and included several histological types of lesions. Ninety-eight 
lesions from 20 melanoma patients were evaluated - The OR rates were 81% with a CR of 
66%. The results confirmed the effectiveness of ECT in the treatment of lesions of different 
histology, demonstrating an 85% objective response rate and a CR rate of 74% for all lesions. 
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These results were independent of the drug used or the route of administration chosen. 
Additionally subsequent studies 11, 49, 66, 89-92 of ECT evaluating its effect in the treatment of 
melanoma and other skin cancers continue to demonstrate the efficacy of the treatment, with 
response rates comparable to the earlier studies, ranging from 46-100%.  
Repeated treatments are feasible as demonstrated by Campana et al.90 and Quaglino et al.11 
producing additional clinical responses in patients who had initial non or partial responses 
or who presented with new recurrent lesions. In the Campana90 study 34 patients out of 52 
were diagnosed with unresectable melanoma, but the response rate for the entire cohort of 
patients treated with either IT or IV Bleomycin improved significantly from a CR of 50%, up 
to 83 % after the third ECT treatments.  
There are approximately 60 institutions in Europe and in the United States that continue to 
investigate and offer ECT as a palliative treatment for a variety of unresectable tumors, 
including melanoma; and in an occasional report it has been used as an alternative curative 
therapy 93. 
6. ECT in the treatment of advanced melanoma 
In patients with unresectable recurrent or in-transit melanoma disease who are not 
candidates for standard surgical or medical treatment, ECT is now an important therapeutic 
option18,43,49,75,84,94. These cases include those with unresectable disease due to the extensive 
number of nodules or lesions located in compromising anatomic areas, such as those around 
joints, nerves, distal leg and in previously operated fields. Encouraging results with long 
term remissions have been documented 17, 45, 78, 93, 95-96. ( Figure 3) 
 
 
 
 
 
 
Fig. 3. A) An Exophytic type recurrent malignant melanoma after isolated limb perfusion.  
B) Six months following treatment by ECT . 
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Author 
No. 
Patients 
Nodules Drug/route CRR % 
ORR 
(PR+CR)% 
Rudolf 1995135 2 24 Bleomycin IV 92 92 
Heller 1996137 3 10 Bleomycin IV 30 50 
Glass 1996140 5 23 Bleomycin IT 78 96 
Heller 1998141 12 84 Bleomycin IT 75 99 
Kubota 1998144 1 8 Bleomycin IT 100 100 
Mir 199827 20 142 Bleomycin IV 53 92 
Sersa 1998146 2 13 Cisplastin IT 100 100 
Sersa 2000147 9 27 Cisplastin IV 11 48 
Sersa 2000153 10 82 Cisplastin IT 80 87 
Rols 2000145 4 55 Bleomycin IV 9 93 
Gehl 2000128 1 9 Bleomycin IT 100 100 
Rodriguez 
2001143 
2 13 Bleomycin IT 23 85 
Sersa 2003149 14 211 Cisplastin IT 70 81 
Byrne 2005144 21 52 Bleomycin IT 63 71 
Snoj 2005148 1 1 Cisplastin IT 0 100 
Marty 2006124 20 98 
Bleomycin IT/IV* 
larger 3 cm 
66 81 
Gaudy 2006159 
12 
(7 per 
protocol) 
30 
23 
Bleomycin IT 
36 
74 
46 
82 
Snoj 2006165 1 16 Cisplastin IT 100 100 
Larkin 2007121 
4 
(2 pts LTF) 
56 
Bleomycin IT or IV 
for nodules > 3 cm 
0 
50 
 
Snoj 2007164 
1 
(RETC x4) 
224 Bleomycin IV 100 100 
Tauceri 2007157 3 ns Bleomycin IT ns ns 
Qualigno 
200812 
14 
(7 pts 
RETC) 
160 
73 
Bleomycin IV 
50 
58 
93 
93 
 
Campana 
2009158 
34 MM 
*(52 cohort 
27 RETC) 
 
373 
608 
257 
 
Bleomycin IT/IV 
ns 
50 
66 
 
ns 
74 
90 
 
IV: Intravenous, IT: Intratumoral, CRR: Complete Response Rate, ORR: Overall Response Rate, PR: 
Partial Response, CR: Complete Response 
RETC: Repeated Electrochemotherapy, LTF: Lost to follow up, ns: No specified, MM: Malignant 
melanoma 
*: Patients with different histological types 
 
Table 2. Summary of most relevant studies using ECT for unresectable or In-Transit 
Melanoma  
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Its effectiveness has been proven when providing palliative treatment for hemorrhagic and 
painful tumor nodules 56-57, 79, 97-98. This is a benefit believed to be secondary to the “vascular 
lock” phenomenon The vasoconstriction at the arteriolar level produces an imediate and 
dramatic reduction of perfusion of the malignant lesions, thus controlling the bleeding 18, 45, 
98. ECT can also be useful as a neoadjuvant treatment for cytoreduction and organ sparing 
treatment. Its benefits has been reported in patients with perineal melanoma treated with 
Cisplatin 85 and for a sphincter saving procedure in anal melanoma 83. 
ECT can also be suitable for and more tolerable by those patients with a prohibitive surgical 
risk due to significant comorbidities52 because the length of the procedure is relatively short 
52 and patients are able to tolerate multiple sessions. In some anatomical locations ECT could 
provide good and sometimes better cosmetic results than surgery 93.  
ECT in combination with cytokine therapy or gene coding immunotherapies has advanced 
to clinical trials in advanced melanoma. In a phase II study, patients treated with injections 
of low dose perilesional IL-2 and ECT with Bleomycin, the cytotoxic T lymphocytes 
response against the known melanoma antigens initially decreased after treatment to 
reappear when IL-2 was stopped. The tumor-specific peripheral T cells could be detected 
later in the lesions. The authors theorized that cell death produced by ECT may have 
attracted and primed denditric cells with the tumor antigens, which later migrated to the 
draining lymph node basin, and elicited a T cell response against those antigens expressed 
by the melanoma100. 
The first Human phase I trial of in vivo DNA electroporation of recurrent malignant 
melanoma was published in the USA in 2009101. EP with dose escalation of the interleukin-12 
plasmid (in vivo DNA EP) was used in the treatment of 24 patients with stage III B/C or IV 
disease. It resulted in significant necrosis of melanoma cells and regression of the majority of 
treated lesions. In addition, clinical regression of untreated lesions suggested the induction 
of systemic anti tumor immune responses. The treatment was found to be safe with no 
significant reported toxicities . While additional studies in larger cohorts of patients are still 
necessary, to obtain reproducibility of these results, these data show a new method of 
inducing potent tumour specific immune responses individual to the patient. 
There are no studies comparing ECT with other surgical modalities, however when taking 
into consideration the learning curve of other complex regional treatment modalities, the 
techniques of ECT are considered to be “user friendly” and easy to teach and learn. This 
technique can also be highly advantageous and useful in countries or hospitals where other 
modalities or resources are limited.45 
7. Advantages of ECT 
1. Excellent local tumor control rates (80-90%) 
2. Minimal risk of damage to healthy surrounding tissue 
3. Lower chemotherapy doses needed, minimizing the toxicity profile of the drug 
4. There is no protein denaturation, which may elicit an undesireable immune response 
against self antigens 
5. High safety profile without severe side effects 
6. Good cost/benefit ratio profile: ambulatory setting, lower cost for drugs, and minimal 
equipment needed. 
7. Treatments are well tolerated by patients 
8. Improvement in the perceived quality of life  
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8. Patient selection and limitations of the procedure 
The contraindications of the ECT could be divided into drug and procedure related. 
A. Drug related contraindications60: 
1. Known allergy to the drug to be administered 
2. Interstitial lung fibrosis, if Bleomycin is going to be used 
3. Kidney failure or limited renal function  
4. When the cumulative dose of Bleomycin has reached >400,000 UI/m2 
B. Procedure related contraindications43: 
1. For safety reasons ECT should not be used in patients with implanted electric devices 
such as pacemakers  
2. In patients who may carry a higher risk of bleeding such as those on anticoagulants or 
with increased INR and platelets count < 70,000. 
9. Limitations 
With the current available electrodes, ECT has limitations when treating deep seated 
tumors43. Tumors larger than 3 cm2 appear to have lower response rates (CR 73 %) to ECT 
11,49,90 as compared to nodules smaller than 1cm2 (CR 98%). These findings were not 
affected by either the cutaneous or subcutaneous location of the nodules 11.  
When tumor nodules are located in irradiated or fibrotic tissues the needle electrode 
penetration may be problematic with a suboptimal delivery of the electrical current or 
drugs 90. Nonetheless, if optimal needle penetration is achieved, ECT is equally effective in 
irradiated as in non-irradiated tissue52. If extensive disease (more than 15 lesions) is present 
repeated sessions may be necessary. In aggressive disease – while undergoing ECT new 
cutaneous nodules may emerge but palliative retreatment is worthwhile eventhough the 
systemic disease progresses rapidly60. 
This treatment modality has not been studied in randomized trials with other treatment 
techniques, such as ablative and perfusion or infusion procedures, or radiation therapy. 
More studies with longer follow up are still needed to evaluate disease free survival and to 
compare ECT to surgical excision, not only in the palliative setting but as a curative 
alternative in those patients unsuitable or unfit for a surgical procedure19. 
10. Toxicity and side effects 
ECT has a low toxicity profile with limited side effects as compared to other regional 
therapies such as HILP or ILP 41. However one of the limitations of fully assessing the 
toxicities of the treatment is the inconsistency of the large majority of the published studies 
documenting complications.  
The systemic dose of Bleomycin is one twentieth of that used in the majority of 
chemotherapeutic regimens and thus the systemic side effects appear to be limited to 
nausea 18, 90. There has been two reported cases of post procedure lypothymia90.  
The most common local side effects reported by the majority of patients are pain (75%) and 
erythema limited to the tumor and surrounding treated tissue 11, 45, 52, 66. Most of the patients 
considered those symptoms tolerable as documented by the ESOPE study 52. The 
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erythematous reaction usually recedes within a few days11. Local tumor necrosis has been 
reported in 42% of cases66. Delayed wound healing that may take several weeks or months 
to resolve, and epidermal erosions, and hematomas have been reported as rare events66,73,75. 
The injection site reactions appear to be low (Type I and II) in the Wiebendirk toxicity 
scale90.  
Transient muscle spasms myoclonus, secondary to muscle stimulation by the electrical 
pulses, have been reported in 25% with lower intensity contractions in up to 78% of 
patients52,66. Some authors advocate the administration of diazepam to alleviate these 
particular symptoms73,75. Interestingly the majority of patients are willing to continue 
treatment if indicated, since the side effects are tolerable19.  
11. What the future holds 
Equipment evolution 
Bioengineering developments and evolution of the technique continue to expand the 
applications of ECT as an alternative treatment for tumors that are inaccessible to current 
electrical probes. A redeveloped electroporator generator provides more flexibility to deliver 
the electric current at different phases of the cardiac cycle and the facility to connect several 
electrode probes around the tumor to deliver the electric pulses in synchrony. The other 
development is related to the type of electrodes. Longer array electrodes are now available 
to treat larger and deeper seated tumors, which in the past was a limitation of the 
procedure. These longer electrodes are insulated proximally to prevent short circuiting of 
current and to protect the normal tissues that are transgressed en-route to the tumor. These 
new devices have recently been applied clinically19, 102-103. Kos et al. 103 have proposed an 
algorithmic computer optimized analysis to treat deeper tumors, to minimize errors and to 
maximize treatment benefits. 
Another novelty is the creation of finger applicators which allows the application of 
electrodes into lesions located in difficult to reach anatomic locations, such as the inside of the 
oral cavity. These finger electrodes have been already tested in the treatment of melanoma of 
the oral mucosa, and head and neck regions, with complete tumor regression 90.  
New endoluminal electrodes to reach internal lesions within the gastrointestinal tract have 
been used in animal models, as well as tumors transplanted into rabbit liver and murine 
models 87, 104-106. These studies are encouraging and have demonstrated both in vitro and in 
vivo (human solid tumor masses in nude mouse models), that the use of flexible electrodes is 
safe, feasible and reproducible.  
There is still the need to create harder needle probes for use in those difficult to treat 
subcutaneous and cutaneous tumors. These needles must be capable of penetrating into 
hard fibrotic tissue, while minimizing the bleeding risks and maintaining an adequate 
electrical distance between the probes.  
Nanopulses 
Higher amplitude electric pulses or “nanopulses” are currently being evaluated. The use of 
shorter pulse durations in the nanosecond range are believed to create smaller pores that 
allow ions but not large molecules to penetrate the membrane. These higher electric fields 
increase the possibility of producing non resealable pores, thus producing the effect of 
irreversible electroporation, and consequently allowing the cells to lose their cytoplasm with 
concomitant cell death. This principle is being used for tumor ablation, palliation or both 43, 
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107-109. However in the treatment of melanoma, the advantages of these higher electric fields 
are not immediately evident. 
ECT combination with Gene transfer, immunology and nanomolecules  
Several studies suggest that the immune system is also involved in the mechanisms of 
response to ECT treatment and that this could be exploited for systemic disease control.  
In a murine model 114, ECT followed by CpG oligonucleotide injection locally, produced an 
enhancement of the complete regression responses of tumors from 43 to 100 % , while also 
triggering systemic antitumor phenomenon with specific immune memory. Activation of 
dendritic cells released from the tumors are believed to be involved in this response with a 
recruitment of CD11c and CD11b receptors and an increase of TLR9 expression .  
EP in combination with gene transfer is termed “Gene Electrotransfer “. It uses gene coding 
plasmids in order to transfer intracellularly a combination of genes, to either knock down 
the expression of a particular gene, or to stimulate temporary patterns of gene expression). 
The technique allows for avoidance of the biohazard issues intrinsic to viral vectors 101, 115-116.  
Scientists at the Cork Cancer Research Centar in Ireland have investigated in an in vivo 
murine model, the application of EP and local gene therapy for malignant tumors. A 
plasmid coding for two immunogenes, granulocyte-macrophage colony-stimulating factor 
(GM-CSF) and the B7-1 co-stimulatory immune molecule were delivered by EP. This 
resulted in the complete regression of the majority (60%) of non immunogenic tumors, while 
eliciting a tumour specific systemic response that hindered the metastatic growth in the liver 
in a 100 % of the mice. This was a durable potent response with tumor specificity. When the 
remaining non responders non responders tumors were excised, an improved survival was 
observed when compared to the control groups, thus suggesting that the use of neoadjuvant 
electroporation and gene therapy given at an appropriate time interval prior to tumour 
excision or ablation could prevent the surfacing of metastatic disease 117-119. Regulatory T cell 
depletion at the time of electrogenetherapy stimulated improved complete response rates 
from 60 to near 100% suggesting a potential for improving efficacy of electroporation based 
immunogene therapy. 
ECT with injection of TNF-α intra or peritumorally and suboptimal doses of Bleomycin in 
mice might have a positive immunomodulatory effect, and possibly adds a systemic 
component to the localized ECT treatment120 . It has been noted that EP with INF-α used to 
treat Mycosis Fungoides (subcutaneous lymphoma) lesions produced a 100 % CR 121 The 
cytotoxic action of INF-α was attributed to its increased tumoral concentration and the 
prolonged time of action produced by the EP. ECT either with INF-α or TNF-α might permit 
the usage of less toxic doses, while enhancing clinical local and systemic immunological 
response rates and minimizing systemic side effects19. 
ECT, radiotherapy and activation of bioreductive drugs 
The “vascular lock” principle of EP has the potential to be used to ”activate” bioreductive 
drugs such as Tirapazamine against neoplastic cells 43, due to its vascular disrupting effect 
of tumor blood supply. In addition ECT has been shown to have a synergistic effect with 
radiotherapy in preclinical investigations, opening the possibility to use it as a 
radiosensitising tool for the palliation of subcutaneous lesion43, 122. 
The continued development of improved diagnostic methods will allow for earlier diagnosis 
of metastases, and possibly open the opportunities for in situ neoadjuvant treatment of 
www.intechopen.com
 
The Role of Electrochemotherapy in the Treatment of Malignant Melanoma 
 
223 
higher risk malignant melanomas by means of immunogene or cytokine therapies, hence 
establishing tumour specific responses which could prevent recurrence and eradicate 
disseminated micometastases. 
12. Summary  
ECT with Bleomycin or Cisplatin is an effective treatment in the palliative management of 
unresectable recurrent cutaneous or subcutaneous melanoma metastases or in-transit 
disease, with OR rates of approximately 80-90%. ECT should now be considered as part of 
the armamentarium for treatment of loco regional advanced melanoma. The technology of 
ECT continues to evolve allowing for the treatment of metastatic lesions in other organs or 
anatomic regions. The principles of EP are already being applied in the clinical setting for 
the delivery of targeted therapies such as gene transfer and immunotherapy. These 
therapies along with ECT have the potential not only for local, but for distant treatment of 
tumors such as those of malignant melanoma, by stimulating a self-driven immune response 
to achieve systemic control of the disease 
However studies evaluating long term follow up results of ECT in melanoma are still 
needed prior to considering it as an option for curative intent. ECT has been proven to be an 
excellent palliative option in treatment of recurrent unresectable or in-transit disease. 
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